Full Text Journal Articles by
Author Steven Joniau

Advertisement

Find full text journal articles






Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.

Gaëtan Devos, Wout Devlies, Gert De Meerleer, Marcella Baldewijns, Thomas Gevaert, Lisa Moris, Daimantas Milonas, Hendrik Van Poppel, Charlien Berghen, Wouter Everaerts, Frank Claessens, Steven Joniau,

Patients with high-risk prostate cancer treated with curative intent are at an increased risk of biochemical recurrence, metastatic progression and cancer-related death compared with patients treated for low-risk or intermediate-risk disease. Thus, these patients often need multimodal therapy to achieve complete disease control. Over the past two decades, multiple studies ... Read more >>

Nat Rev Urol (Nature reviews. Urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Supportive care needs and utilization of bladder cancer patients undergoing radical cystectomy: A longitudinal study.

Elke Rammant, Ann Van Hecke, Karel Decaestecker, Maarten Albersen, Steven Joniau, Wouter Everaerts, Femke Jansen, Nihal E Mohamed, Roos Colman, Mieke Van Hemelrijck, Valérie Fonteyne,

<h4>Objectives</h4>Investigating supportive care (SC) needs and utilization/willingness to use SC services from diagnosis to one year after radical cystectomy in bladder cancer (BC) patients. MATERIALS & METHODS: A longitudinal cohort study was conducted in 90 BC patients at Ghent/Leuven University Hospitals between April 2017 and December 2020. The Supportive Care Needs ... Read more >>

Psychooncology (Psycho-oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.

Tim Muilwijk, Murat Akand, Sofie Daelemans, Koen Marien, Yannick Waumans, Mark Kockx, Loïc Baekelandt, Thomas Van den Broeck, Frank Van der Aa, Thomas Gevaert, Steven Joniau,

Fibroblast activation protein-α (FAP) is a transmembrane peptidase and a surrogate marker for cancer-associated fibroblasts (CAFs). FAP has been linked to worse prognosis and therapy resistance in several cancers. We hypothesised that FAP might have a prognostic 3biomarker potential to stratify patients with high-grade (HG) T1 non-muscle-invasive bladder cancer (NMIBC). ... Read more >>

PLoS One (PloS one)
[2021, 16(9):e0257195]

Cited: 0 times

View full text PDF listing >>



Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications.

Eduard Roussel, Lisa Kinget, Annelies Verbiest, Bram Boeckx, Jessica Zucman-Rossi, Gabrielle Couchy, Stefano Caruso, Marcella Baldewijns, Steven Joniau, Hendrik Van Poppel, Diether Lambrechts, Maarten Albersen, Benoit Beuselinck,

<h4>Background</h4>Glandular metastases (GM) have been associated with improved survival in metastatic clear cell renal cell carcinoma (m-ccRCC). We aimed to molecularly characterize m-ccRCC with GM.<h4>Material and methods</h4>We performed a retrospective cohort study on all m-ccRCC patients with available tissue at our institution, diagnosed with metastatic disease from 2000 to 2019. ... Read more >>

Acta Oncol (Acta oncologica (Stockholm, Sweden))
[2021, :1-8]

Cited: 0 times

View full text PDF listing >>



Elective nodal radiotherapy in prostate cancer.

Gert De Meerleer, Charlien Berghen, Alberto Briganti, Christof Vulsteke, Julia Murray, Steven Joniau, Anne M Leliveld, Cesare Cozzarini, Karel Decaestecker, Kato Rans, Valerie Fonteyne, Olivier De Hertogh, Alberto Bossi,

In patients with prostate cancer who have a high risk of pelvic nodal disease, the use of elective whole pelvis radiotherapy is still controversial. Two large, randomised, controlled trials (RTOG 9413 and GETUG-01) did not show a benefit of elective whole pelvis radiotherapy over prostate-only radiotherapy. In 2020, the POP-RT ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(8):e348-e357]

Cited: 0 times

View full text PDF listing >>



High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer.

Carolin Eckhardt, Iuliu Sbiera, Markus Krebs, Silviu Sbiera, Martin Spahn, Burkhard Kneitz, Steven Joniau, Martin Fassnacht, Hubert Kübler, Isabel Weigand, Matthias Kroiss,

<h4>Background</h4>Prostate cancer (PCa) is the most frequent cancer in men. The prognosis of PCa is heterogeneous with many clinically indolent tumors and rare highly aggressive cases. Reliable tissue markers of prognosis are lacking. Active cholesteryl ester synthesis has been associated with prostate cancer aggressiveness. Sterol-O-Acyl transferases (SOAT) 1 and 2 ... Read more >>

Prostate Cancer Prostatic Dis (Prostate cancer and prostatic diseases)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer.

Sander Jentjens, Cindy Mai, Niloefar Ahmadi Bidakhvidi, Liesbeth De Coster, Nathalie Mertens, Michel Koole, Wouter Everaerts, Steven Joniau, Raymond Oyen, Koen Van Laere, Karolien Goffin,

<h4>Objectives</h4>PSMA-PET has become the PET technique of choice to localise the site of biochemically recurrent prostate cancer (PCa). With hybrid PET/MRI, the advantages of MRI are added to molecular characteristic of PET. The aim of this study was to investigate the incremental value of PET/MR versus PET/CT in patients with ... Read more >>

Eur Radiol (European radiology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials.

Eduard Roussel, Annelies Verbiest, Lisa Kinget, Bram Boeckx, Jessica Zucman-Rossi, Gabrielle Couchy, Stefano Caruso, Sylvie Job, Aurélien de Reyniès, Liesbeth De Wever, Marcella Baldewijns, Hendrik Van Poppel, Steven Joniau, Diether Lambrechts, Maarten Albersen, Benoit Beuselinck,

<h4>Background</h4>Trials with adjuvant vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) failed to demonstrate meaningful benefit in clinically high-risk, fully resected clear cell renal cell carcinoma (ccRCC). We evaluated whether the ccrcc1-4 molecular subtypes and gene expression signatures (GES) are associated with outcomes in this setting.<h4>Materials and methods</h4>We determined ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series.

Keith J Kowalczyk, Rabii H Madi, Christopher G Eden, Prasanna Sooriakumaran, Karen Fransis, Yannic Raskin, Steven Joniau, Scott Johnson, Kenneth Jacobsohn, Antonio Galfano, Aldo M Bocciardi, Jonathan Hwang, Isaac Y Kim, Jim C Hu,

<h4>Purpose</h4>Salvage radical prostatectomy (SRP) is rare due to the risk of postoperative complications. We compare salvage Retzius-sparing robotic assisted radical prostatectomy (SRS-RARP) with salvage standard robotic assisted radical prostatectomy (SS-RARP).<h4>Materials and methods</h4>A total of 72 patients across 9 centers were identified (40 SRS-RARP vs 32 SS-RARP). Demographics, perioperative data, and ... Read more >>

J Urol (The Journal of urology)
[2021, :101097JU0000000000001939]

Cited: 0 times

View full text PDF listing >>



Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.

Carlo A Bravi, Matteo Droghetti, Nicola Fossati, Giorgio Gandaglia, Nazareno Suardi, Elio Mazzone, Vito Cucchiara, Simone Scuderi, Francesco Barletta, Riccardo Schiavina, Daniar Osmonov, Klaus-Peter Juenemann, Luca Boeri, R Jeffrey Karnes, Alexander Kretschmer, Alexander Buchner, Christian Stief, Andreas Hiester, Alessandro Nini, Peter Albers, Gaëtan Devos, Steven Joniau, Hendrik Van Poppel, Bernhard Grubmüller, Shahrokh F Shariat, Axel Heidenreich, David Pfister, Derya Tilki, Markus Graefen, Inderbir S Gill, Alexandre Mottrie, Pierre I Karakiewicz, Francesco Montorsi, Alberto Briganti,

<h4>Background</h4>The optimal definition and prognostic significance of persistently elevated prostate-specific antigen (PSA) after salvage lymph node dissection (sLND) for node-only recurrent prostate cancer (PCa) remain unknown.<h4>Objective</h4>To assess the definition and clinical implications of persistently elevated PSA after sLND for node-only recurrent PCa after radical prostatectomy.<h4>Design, setting, and participants</h4>The study included ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



In Regard to Zelefsky et al.

Kato Rans, Gert De Meerleer, Steven Joniau, Adinda Baten, Patrick Berkovic, Maarten Lambrecht, Charlien Berghen,

Int J Radiat Oncol Biol Phys (International journal of radiation oncology, biology, physics)
[2021, 110(3):910-911]

Cited: 0 times

View full text PDF listing >>



Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.

Tim Muilwijk, Murat Akand, Frank Van der Aa, Vincent De Coninck, Marc Claessens, Robert Hente, Markus Eckstein, Yves Allory, Louis Libbrecht, Steven Joniau, Thomas Gevaert,

Cytokeratin 5 is a marker of basal molecular subtypes of muscle-invasive bladder cancer (MIBC), which correlates with worse overall survival compared to luminal subtypes. Our observations have not confirmed CK5 as a marker of high-grade (HG) disease in Ta non-muscle-invasive bladder cancer (NMIBC). Therefore, to understand the basal-luminal immunohistochemistry profile ... Read more >>

J Cell Mol Med (Journal of cellular and molecular medicine)
[2021, 25(16):7890-7900]

Cited: 1 time

View full text PDF listing >>



Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study.

Lorenzo Tosco, Gaëtan Devos, Laura Schillebeeckx, Steven Pans, Karolien Goffin, Wouter Everaerts, Hendrik Van Poppel, Steven Joniau,

<h4>Background</h4>Despite the curative intent of radical prostatectomy (RP) (+/- radiotherapy (RT)), 30% of the clinically localized prostate cancer (CaP) patients will develop rising PSA (prostate specific antigen). In absence of clinical recurrence, there is a lack of effective treatment strategies in order to control the disease at its earliest (micro)metastatic ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Is the Age of Extended Pelvic Lymph Node Dissection Over? The Devil Is in the Details.

Gaëtan Devos, Andries Clinckaert, Gert De Meerleer, Steven Joniau,

Eur Urol Oncol (European urology oncology)
[2021, 4(4):540-542]

Cited: 0 times

View full text PDF listing >>



Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.

Beat Foerster, Mohammad Abufaraj, Surena F Matin, Mounsif Azizi, Mohit Gupta, Wei-Ming Li, Thomas Seisen, Timothy Clinton, Evanguelos Xylinas, M Carmen Mir, Donald Schweitzer, Andrea Mari, Shoji Kimura, Marco Bandini, Romain Mathieu, Ja H Ku, Gautier Marcq, Georgi Guruli, Markus Grabbert, Anna K Czech, Tim Muilwijk, Armin Pycha, David D'Andrea, Firas G Petros, Philippe E Spiess, Trinity Bivalacqua, Wen-Jeng Wu, Morgan Rouprêt, Laura-Maria Krabbe, Kees Hendricksen, Shin Egawa, Alberto Briganti, Marco Moschini, Vivien Graffeille, Wassim Kassouf, Riccardo Autorino, Axel Heidenreich, Piotr Chlosta, Steven Joniau, Francesco Soria, Phillip M Pierorazio, Shahrokh F Shariat,

<h4>Background</h4>Several groups have proposed features to identify low-risk patients who may benefit from endoscopic kidney-sparing surgery in upper tract urothelial carcinoma (UTUC).<h4>Objective</h4>To evaluate standard risk stratification features, develop an optimal model to identify ≥pT2/N+ stage at radical nephroureterectomy (RNU), and compare it with the existing unvalidated models.<h4>Design, setting, and participants</h4>This ... Read more >>

Eur Urol (European urology)
[2021, 80(4):507-515]

Cited: 0 times

View full text PDF listing >>



Male Wolffian adnexal tumor: the first report of long-term follow-up after radical surgical treatment.

Daimantas Milonas, Edwin Steenkiste, Rita De Vos, Philippe Moerman, Evelin Lerut, Steven Joniau,

The male Wolffian tumor is an extremely rare case in male patients. Here, we report a patient with such malignancy and successful radical surgical treatment at 15-year follow-up. The clinicopathological, immunohistochemical, and ultrastructural features are described. The differential diagnosis of this tumor in a male patient is discussed. ... Read more >>

Curr Urol (Current urology)
[2021, 15(2):126-128]

Cited: 0 times

View full text PDF listing >>



Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer.

Niloefar Ahmadi Bidakhvidi, Annouschka Laenen, Sander Jentjens, Christophe M Deroose, Koen Van Laere, Liesbeth De Wever, Cindy Mai, Charlien Berghen, Gert De Meerleer, Karin Haustermans, Steven Joniau, Wouter Everaerts, Karolien Goffin,

<h4>Background</h4>Detection of the site of recurrence using PSMA-PET/CT is important to guide treatment in patients with biochemical recurrence of prostate cancer (PCa). The aim of this study was to evaluate the positivity rate of [<sup>18</sup>F]PSMA-1007-PET/CT in patients with biochemically recurrent PCa and identify parameters that predict scan positivity as well ... Read more >>

EJNMMI Res (EJNMMI research)
[2021, 11(1):41]

Cited: 0 times

View full text PDF listing >>



The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study.

Sinan Khadhouri, Kevin M Gallagher, Kenneth R MacKenzie, Taimur T Shah, Chuanyu Gao, Sacha Moore, Eleanor F Zimmermann, Eric Edison, Matthew Jefferies, Arjun Nambiar, Miles P Mannas, Taeweon Lee, Giancarlo Marra, Beatrice Lillaz, Juan Gómez Rivas, Jonathan Olivier, Mark A Assmus, Taha Uçar, Francesco Claps, Matteo Boltri, Tara Burnhope, Nkwam Nkwam, George Tanasescu, Nicholas E Boxall, Alison P Downey, Asim A Lal, Marta Antón-Juanilla, Holly Clarke, David H W Lau, Kathryn Gillams, Matthew Crockett, Matthew Nielsen, Yemisi Takwoingi, Naomi Chuchu, John O'Rourke, Graeme MacLennan, John S McGrath, Veeru Kasivisvanathan, ,

<h4>Objective</h4>To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation.<h4>Patients and methods</h4>This was an international multicentre prospective observational study. We included patients aged ≥16 years, ... Read more >>

BJU Int (BJU international)
[2021, :]

Cited: 0 times

View full text PDF listing >>



68Ga-PSMA-11 PET, 18F-PSMA-1007 PET, and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Intertracer Variability.

Cédric Draulans, Floris Pos, Robert J Smeenk, Linda Kerkmeijer, Wouter V Vogel, James Nagarajah, Marcel Janssen, Cindy Mai, Stijn Heijmink, Marloes van der Leest, Patrik Zámecnik, Raymond Oyen, Sofie Isebaert, Frederik Maes, Steven Joniau, Martina Kunze-Busch, Robin De Roover, Gilles Defraene, Uulke A van der Heide, Karolien Goffin, Karin Haustermans,

<h4>Purpose</h4>To assess the intermodality and intertracer variability of gallium-68 (<sup>68</sup>Ga)- or fluorine-18 (<sup>18</sup>F)-labeled prostate-specific membrane antigen (PSMA) positron emission tomography (PET) and biparametric magnetic resonance imaging (bpMRI)-based gross tumor volume (GTV) delineation for focal boosting in primary prostate cancer.<h4>Methods</h4>Nineteen prospectively enrolled patients with prostate cancer underwent a PSMA PET/MRI scan, ... Read more >>

Pract Radiat Oncol (Practical radiation oncology)
[2021, 11(3):202-211]

Cited: 0 times

View full text PDF listing >>



Impact of Grade Groups on Prostate Cancer-Specific and Other-Cause Mortality: Competing Risk Analysis from a Large Single Institution Series.

Daimantas Milonas, Tomas Ruzgas, Zilvinas Venclovas, Mindaugas Jievaltas, Steven Joniau,

<i>Objective:</i> To assess the risk of cancer-specific mortality (CSM) and other-cause mortality (OCM) using post-operative International Society of Urological Pathology Grade Group (GG) model in patients after radical prostatectomy (RP). <i>Patients and Methods:</i> Overall 1921 consecutive men who underwent RP during 2001 to 2017 in a single tertiary center were ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(8):]

Cited: 1 time

View full text PDF listing >>



Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer.

David D'Andrea, Francesco Soria, Anne J Grotenhuis, Eugene K Cha, Nuria Malats, Savino Di Stasi, Steven Joniau, Tommaso Cai, Bas W G van Rhijn, Jaques Irani, Jeffrey Karnes, John Varkarakis, Jack Baniel, Joan Palou, Marek Babjuk, Martin Spahn, Peter Ardelt, Renzo Colombo, Vincenzo Serretta, Guido Dalbagni, Paolo Gontero, Riccardo Bartoletti, Stephane Larré, Per-Uno Malmstrom, Richard Sylvester, Shahrokh F Shariat,

<h4>Purpose</h4>To investigate the association of patients' sex with recurrence and disease progression in patients treated with intravesical bacillus Calmette-Guérin (BCG) for T1G3/HG urinary bladder cancer (UBC).<h4>Materials and methods</h4>We analyzed the data of 2635 patients treated with adjuvant intravesical BCG for T1 UBC between 1984 and 2019. We accounted for missing ... Read more >>

World J Urol (World journal of urology)
[2021, :]

Cited: 1 time

View full text PDF listing >>



Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.

Gautier Marcq, Beat Foerster, Mohammad Abufaraj, Surena F Matin, Mounsif Azizi, Mohit Gupta, Wei-Ming Li, Thomas Seisen, Timothy Clinton, Evanguelos Xylinas, M Carmen Mir, Donald Schweitzer, Andrea Mari, Shoji Kimura, Marco Bandini, Romain Mathieu, Ja H Ku, Georgi Guruli, Markus Grabbert, Anna K Czech, Tim Muilwijk, Armin Pycha, David D'Andrea, Firas G Petros, Philippe E Spiess, Trinity Bivalacqua, Wen-Jeng Wu, Morgan Rouprêt, Laura-Maria Krabbe, Kees Hendricksen, Shin Egawa, Alberto Briganti, Marco Moschini, Vivien Graffeille, Riccardo Autorino, Patricia John, Axel Heidenreich, Piotr Chlosta, Steven Joniau, Francesco Soria, Phillip M Pierorazio, Shahrokh F Shariat, Wassim Kassouf,

<h4>Background</h4>The European Association of Urology risk stratification dichotomizes patients with upper tract urothelial carcinoma (UTUC) into two risk categories.<h4>Objective</h4>To evaluate the predictive value of a new classification to better risk stratify patients eligible for kidney-sparing surgery (KSS).<h4>Design, setting, and participants</h4>This was a retrospective study including 1214 patients from 21 centers ... Read more >>

Eur Urol Focus (European urology focus)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer.

Wout Devlies, Florian Handle, Gaëtan Devos, Steven Joniau, Frank Claessens,

Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies consequently focus on blocking the androgen receptor pathway. Clinical studies reported tumor resistance mechanisms by reactivating and bypassing the androgen pathway. Preclinical models allowed the identification, confirmation, and thorough study of these pathways. This review looks into the current and ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(4):]

Cited: 1 time

View full text PDF listing >>



Re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.040: Time for a Change? Clinically Meaningful Reasons Why We Will Continue Performing Extended Pelvic Lymph Node Dissection in Selected Patients with Prostate Cancer.

Alberto Briganti, Giorgio Gandaglia, Markus Graefen, Steven Joniau, R Jeffrey Karnes, Francesco Montorsi,

Eur Urol (European urology)
[2021, 79(5):e154-e156]

Cited: 0 times

View full text PDF listing >>



Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold.

Zilvinas Venclovas, Tim Muilwijk, Aivaras J Matjosaitis, Mindaugas Jievaltas, Steven Joniau, Daimantas Milonas,

<i>Introduction</i>: The aim of the study was to compare the performance of the 2012 Briganti and Memorial Sloan Kettering Cancer Center (MSKCC) nomograms as a predictor for pelvic lymph node invasion (LNI) in men who underwent radical prostatectomy (RP) with pelvic lymph node dissection (PLND), to examine their performance and ... Read more >>

J Clin Med (Journal of clinical medicine)
[2021, 10(5):]

Cited: 1 time

View full text PDF listing >>



Advertisement


Disclaimer

1.0898 s